PROSTIN E2 Rx
Generic Name and Formulations:
Dinoprostone 20mg; per vaginal suppository.
Indications for PROSTIN E2:
For the termination of pregnancy from the 12th through the 20th gestational weeks. For the evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age. Management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).
Insert one supp high into vagina. Remain in supine position for 10mins following insertion. May insert subsequent supp at 3–5hr intervals until abortion occurs. Continuous administration for more than 2 days is not recommended.
Acute pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease.
Not indicated if fetus in utero has reached the stage of viability. Not for use in cervical ripening or other indication in patients with term pregnancy. Asthma. Hypo-or hypertension. Anemia. Jaundice. Diabetes. Epilepsy. History of cardiac, renal, or hepatic disease. Cervicitis. Infected endocervical lesions. Acute vaginitis. Compromised (scarred) uteri. Remove supp if hypersensitivity reaction is suspected. Pregnancy.
Concomitant other oxytocic agents: not recommended.
Vomiting, transient pyrexia (see full labeling re: PGEs induced pyrexia vs. endometritis pyrexia), diarrhea, nausea, headache, chills, transient decrease in BP; MI in patients with history of CVD, hypersensitivity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML